MED4

Across TCGA pan-cancer cohorts, MED4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED4 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MED4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MED4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where MED4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.987	0.299	.004	8	view →
HNSC	DFS	Median	All	0.991	0.913	.007	5	view →
LSCC	OS	Median	II,III,IV	0.890	0.616	.014	5	view →
OV	DFS	Tertile	All	0.828	1.000	.045	4	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.221	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED4–LUAD (OS)

Open the LUAD breakdown →